Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples | Haematologica
![Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients](https://www.frontiersin.org/files/Articles/575168/fonc-10-575168-HTML/image_m/fonc-10-575168-t002.jpg)
Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
![Neuropathy associated with IgA monoclonal Gammopathy. A harbinger of AL amyloidosis - Journal of the Neurological Sciences Neuropathy associated with IgA monoclonal Gammopathy. A harbinger of AL amyloidosis - Journal of the Neurological Sciences](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/81ea0360-383c-467c-9443-bd82ff7868fb/gr1.jpg)
Neuropathy associated with IgA monoclonal Gammopathy. A harbinger of AL amyloidosis - Journal of the Neurological Sciences
![Cardiac amyloidosis: An underdiagnosed/underappreciated disease - European Journal of Internal Medicine Cardiac amyloidosis: An underdiagnosed/underappreciated disease - European Journal of Internal Medicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d2244edd-6b22-42be-8289-107cdd8d83d7/ga1_lrg.jpg)
Cardiac amyloidosis: An underdiagnosed/underappreciated disease - European Journal of Internal Medicine
![Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment? in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020) Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment? in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020)](https://jnccn.org/view/journals/jnccn/18/12.5/full-jnccn20-5043f1.jpg)
Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment? in: Journal of the National Comprehensive Cancer Network Volume 18 Issue 12.5 (2020)
OAB-001 Potentiating T cell activity against multiple myeloma through SUMOylation inhibition Li Du1, Dennis Awuah1, Wei Liu2, En
Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples | Haematologica
![All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1613cdc1-b321-464f-b17b-ec4249d7b88e/gr1_lrg.jpg)
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer
![A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d0668b16-6f13-4a1b-99c6-7416a2f7b1b3/ctm2346-fig-0002-m.jpg)
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library
![Biomolecules | Free Full-Text | Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation | HTML Biomolecules | Free Full-Text | Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation | HTML](https://www.mdpi.com/biomolecules/biomolecules-10-01387/article_deploy/html/images/biomolecules-10-01387-g001.png)